ps://www.youtube.com/watch?v=Rlfs6hthwGo", "range": {"length":18, "start":172}, "type": "lin k"}],"identifier":" anf-body- 49","inlineTextStyles": [{"range": {"length":234,"start":0},"textStyle":" anf-ts- i"}, {"range™: {"length":234,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"Since Labor Day, Mr. Menendeza這s campaign, perhaps ina sign of vulnerability, has aggressively ramped up its advertising campaign, with a majority of the political attacks accusing Mr. Hugin of raising drug prices to maximize profits.","type":"text"}, {"identifier":" anf-body- 50", "inlineTextStyles": [{"range": {"length":332,"start":0},"textsStyle":" anf-ts- i"}, {"range™: {"length":332,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"In 2017, after Mr. Hugin had stepped down as chief executive and become executive chairman, the company suffered two major setbacks in its development pipeline: A drug it had hoped would be a breakthrough in treating Crohnda€™s disease failed to outperform a control group and Otezla, a psoriasis drug, badly missed sales expectations.","type™:"text"}, {"additions"™: [{"URL":"https://ir.celgene.com/press-— releases/press-release-details/2017/Celgene-Provides-Update-on-GED-0301-mongersen- Inflammatory-Bowel-Disease- Program/default.aspx", "range": {"length":39, "start":21},"type"™:"link"}, {"URL":"https://i r.celgene.com/press-releases/press-release-details/2017/Celgene-Provides-Update-on-GED- 0301-mongersen-Inflammatory-Bowel-Disease- Program/default.aspx", "range":{"length":20,"start":60}, "type"™:"link"}, {"URL":"https://w ww.streetinsider.com/Analyst+Comments/Celgene+%28CELG%29%3A+PricetIncreasestAdd+8ct+intl T+- +Suntrust/13411298 html", "range": {"length":64, "start ":161}, "type":"link"}], "identifier" 27" anf-body- 51", "inlineTextStyles":[{"range": {"length":364,"start":0},"textsStyle":" anf-ts- i"},{"range™:{"length":364,"start":0},"textStyle":" anf-ts-1"}],"layout":"default